Shots:

• The companies collaborated to advance two HLAs that can be utilized to broaden therapy options & develops cell lines that target rare cancers and autoimmune diseases
• NexImmune will use Selexis’ SUREtechnology platform to reduce the time, effort, and costs related to the development of high-performance mammalian cell lines. The HLA IgG4 fusion proteins and T cell co-stimulatory mAb will be produced using Selexis-generated cell lines and added to NexImmune's exclusive AIM injectable nanoparticle technology
• The agreement supports the development of molecules targeting AML, MM, HPV-associated tumors, and additional HLAs to increase immunotherapy options for patients

Ref: Businessswire | Image: Selexis